10901nam 2200637 450 991048872450332120230621114604.03-030-71621-X(CKB)5590000000523706(MiAaPQ)EBC6665412(Au-PeEL)EBL6665412(OCoLC)1259592836(PPN)260302112(EXLCZ)99559000000052370620220322d2021 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierEssentials of tissue and cells banking /George Galea, Marc Turner and Sharon Zahra (editors)Second edition.Cham, Switzerland :Springer,[2021]©20211 online resource (288 pages)3-030-71620-1 Includes bibliographical references and index.Intro -- Preface -- Contents -- 1 Live Donors of Tissue -- Abstract -- 1.1 Introduction -- 1.2 Regulation -- 1.3 Donor Identification -- 1.3.1 Femoral Head Donation -- 1.3.2 Amniotic Membrane Donation -- 1.4 Consent -- 1.5 Donor Selection: Evidence Base and General Considerations -- 1.6 Generic Contraindications -- 1.6.1 Transmissible Infections -- 1.6.2 Acute Infections -- 1.6.3 Risk of Transmission of Prion Diseases -- 1.6.4 Malignancy -- 1.7 Retrieval/Procurement -- 1.8 Summary -- References -- 2 Deceased Tissue Donors -- Abstract -- 2.1 Introduction -- 2.2 Deceased Tissue Donor Identification -- 2.3 The Law and the Role of the Family -- 2.4 Age Cut-Offs -- 2.5 Medical, Behavioural and Social Assessment -- 2.6 Blood Sampling and Haemodilution -- 2.7 Timing and Venue of Retrieval -- 2.8 Retrieval Process -- 2.9 Conclusion -- References -- 3 Banking and Use of Umbilical Cord Blood -- Abstract -- 3.1 Introduction -- 3.2 Donation Programmes -- 3.2.1 Collection Sites -- 3.2.2 Recruitment and Consent -- 3.2.3 Donor Elegibility -- 3.2.4 Collection Techniques -- 3.2.5 Donor Follow up -- 3.2.6 Non-Frozen Transportation -- 3.3 Umbilical Cord Blood Processing and Storage -- 3.3.1 Banking Structure and Resources -- 3.3.2 Reception and Process Acquisition -- 3.3.3 Volume Reduction -- 3.3.4 Cryopreservation -- 3.3.5 Testing and Product Conformity -- 3.3.6 Inventory Management -- 3.4 Use of Umbilical Cord Blood for Transplantation -- 3.4.1 Selection Principles -- 3.4.2 Request for Shipping -- 3.4.3 Frozen Transportation -- 3.4.4 Thawing and Infusion -- 3.4.5 Transplantation Outcomes -- 3.5 Future Challenges for Umbilical Cord Blood Banking -- References -- 4 Ocular Tissue Banking -- Abstract -- 4.1 Eye Donation -- 4.2 Corneal Transplantation -- 4.3 Corneal Storage -- 4.4 Hypothermia -- 4.5 Organ Culture -- 4.6 Limbal Stem Cells.4.7 Extending the Role of Eye Banks -- 4.8 Other Cell-Based Therapies for Ocular Disease -- References -- 5 Banking of Heart Valves -- Abstract -- 5.1 Introduction -- 5.2 Selection Criteria -- 5.3 Processing and Disinfection of Heart Valves -- 5.4 Quality Assurance of Heart Valves -- 5.5 Current Issues in Heart Valve Banking -- 5.5.1 Mechanical Properties of Valves -- 5.6 Decellularization -- 5.7 Vitrification -- 5.8 Matching of Valves -- 5.9 Centralised Supply -- 5.10 Conclusions -- References -- 6 Cryopreservation and Banking of Haematopoietic Progenitor Cells -- Abstract -- 6.1 Introduction -- 6.2 Transportation of HPC Product from the Collection Site to Stem Cell Laboratory -- 6.3 Receipt and Initial Storage of HPC Products -- 6.4 Preparation of HPC Products for Cryopreservation -- 6.5 Cryopreservation of HPC Products -- 6.6 Rate of Freezing -- 6.7 Storage of HPC Products -- 6.8 Transport of Frozen HPC Products -- 6.9 Further Processing Performed by Stem Cell Laboratories -- 6.9.1 Bone Marrow (HPC,M) Processing -- 6.9.2 Selection/Depletion -- 6.9.3 Campath in the Bag -- 6.10 Quality Control of the HPC Product -- 6.11 Quality Control Post Cryopreservation -- 6.12 Conclusion -- References -- 7 Storage, Processing and Preservation -- Abstract -- 7.1 Introduction -- 7.1.1 Tissue Replacement -- 7.1.2 Autologous Versus Allogeneic Grafts -- 7.1.3 Immunological Reponses to Tissue Allografts -- 7.2 Principles of Tissue Preservation -- 7.2.1 Preservation of Non Viable Tissue Grafts -- 7.2.1.1 Causes of Degradation -- 7.2.1.2 Reduction of Water Activity -- Freeze-Drying (Lyophilisation) -- Deep Freezing -- High Concentration Solutes -- 7.2.1.3 Cell Removal -- 7.2.2 Preservation of Viable Tissue Grafts -- 7.3 Principles of Disinfection and Sterilisation -- 7.3.1 Definitions -- 7.3.2 Disinfection Methods -- 7.3.2.1 Viable Tissues -- 7.3.2.2 Non-viable Tissues.7.3.3 Sterilisation Methods -- 7.3.3.1 Physical Methods -- 7.3.3.2 Chemical Methods -- References -- 8 Cryopreservation in Tissue Banking -- Abstract -- 8.1 Introduction -- 8.2 Critical Impact of Ice Formation -- 8.3 The Role of Added Cryoprotectants -- 8.4 Sample Thawing -- 8.5 Spheroid and Organoid Cryopreservation -- 8.6 Toward the Cryopreservation of Organs and Biopsies -- 8.7 Quality Issues -- 8.8 Sterility, Handling and Contamination Issues -- 8.9 Conclusion -- References -- 9 Sterilisation by Irradiation -- Abstract -- 9.1 Introduction -- 9.2 Specificity of Radiation Sterilisation with Gamma Rays and Electron Beams -- 9.3 Dosimetry for Radiation Sterilisation -- 9.4 Mechanisms Involved in the Inactivation of Micro-organisms by Ionising Radiation -- 9.5 Radiation Resistance of Micro-organisms -- 9.6 Summary and Conclusions -- References -- 10 Screening the Tissue Donor for Infectious Agents -- Abstract -- 10.1 Introduction -- 10.2 Sample Quality -- 10.2.1 Living v. Deceased Donors -- 10.2.1.1 Donor Selection -- 10.2.1.2 Laboratory Screening -- 10.2.2 Haemodilution -- 10.2.3 Screening Targets -- 10.3 Range of Infectious Agents -- 10.3.1 Mandatory Screening -- 10.3.2 Additional/Selective Screening -- 10.3.3 Screening for Other Infectious Agents -- 10.4 Emerging Infectious Threats -- 10.5 Screening Strategy -- 10.5.1 Screening Algorithms -- 10.6 Screening Assays -- 10.6.1 Serological Screening Assays -- 10.6.2 Molecular Screening Assays -- 10.7 Residual Risk -- 10.7.1 Window Period -- 10.8 Conclusions -- References -- 11 Contamination in the Tissue Way -- Abstract -- 11.1 Introduction -- 11.1.1 Bacteria and Fungi -- 11.2 The Tissue Way, P.L.C. Petit [22] -- 11.2.1 Donor -- 11.2.2 Tissue Retrieval in mortuary (1) or operating theatre (2) -- 11.2.3 Transport -- 11.2.4 Tissue Establishment -- 11.2.5 Microbiology Laboratory -- 11.3 Specific Items.11.4 Future -- References -- 12 Establishing a Quality System in a Tissue Establishment -- 12.1 Background -- 12.2 The History of Quality Management -- 12.3 Why a Quality Management System -- 12.4 Why Quality? -- 12.5 What is Quality? -- 12.6 Examples of Methods to Be Used in Quality -- 12.7 Available Standards and International Legal Documents -- 12.8 Setting Up a Quality System -- 12.9 Risk Management -- 12.10 Applying a Quality System to Your Activities -- 12.10.1 Where Do I Start? -- 12.11 Biovigilance -- 12.12 Quality Systems and IT -- 12.13 Data Protection -- 12.14 The Cost of Quality -- 12.14.1 The Cost of Quality Can Be Categorized into Four Categories -- 12.15 Role of Management and Quality Management Review -- 12.16 Conclusion -- References -- 13 IT System Requirements for Tissue and Cell Banking -- Abstract -- 13.1 Introduction -- 13.2 Why Introduce an IT System? -- 13.3 The Benefits of an IT System -- 13.4 What Are the Operational Requirements? -- 13.5 Developing the Operational Requirements Document (ORD) -- 13.5.1 Functional Requirements -- 13.5.2 Non-functional Requirements -- 13.6 Technology Solutions -- 13.7 Managing the Data -- 13.7.1 Barcodes -- 13.7.2 Radio Frequency Identification (RFID) -- 13.7.3 OCR/ICR/Touch Screens -- 13.7.4 Electronic System Interfaces -- 13.8 Database Management Technology -- 13.9 Selecting an IT System -- 13.10 Cost of an IT System -- 13.11 Implementing an IT System -- 13.11.1 Define Success -- 13.11.2 Set Priorities -- 13.11.3 Avoid Modifications -- 13.11.4 Prepare for Change -- 13.11.5 Gain Executive Support -- 13.11.6 People -- 13.12 Implementation Approach -- 13.13 System Validation -- 13.14 User Training -- 13.15 Managing an IT System -- 13.16 Conclusions -- References -- 14 Ethical and Regulatory Aspects of Cell and Tissue Banking -- Abstract -- 14.1 Introduction -- 14.2 Ethical Issues.14.2.1 Donor Consent -- 14.2.1.1 Types of Consent -- 14.2.1.2 Capacity to Consent -- Saviour Siblings -- Cord Blood -- 14.2.1.3 Informed Consent -- 14.2.2 Voluntary Donation -- 14.2.3 Property Rights -- 14.2.3.1 Commercialisation -- 14.2.4 Confidentiality -- 14.2.5 Certification of Death -- 14.2.6 Just Access -- 14.2.7 Safety Issues -- 14.2.7.1 Infrastructure and Procedures -- 14.2.7.2 Healthcare Personnel -- 14.3 Societal Issues -- 14.3.1 Altruism -- 14.3.2 Education -- 14.3.3 Cross-Border Exchange -- 14.3.4 Trafficking -- 14.4 Regulatory Instruments -- 14.4.1 Donor Consent -- 14.4.2 Transplant Institutions -- 14.4.3 Data Protection -- 14.4.4 Training -- 14.5 Special Considerations for Cellular Therapies -- 14.5.1 Capacity to Consent -- 14.5.2 Limits of Certainty of Consent -- 14.5.3 Scope of Consent -- 14.5.4 Duration of Consent -- 14.5.5 Commercialisation -- 14.6 The Future -- 15 Human Embryonic Stem Cell Banking for Clinical Applications-20 Years from Their Isolation -- Abstract -- 15.1 Introduction -- 15.2 Human Embryonic Versus Induced Pluripotent Stem Cells as Clinical Source Material -- 15.3 Human Embryonic Stem Cell-Based Therapies -- 15.3.1 Currently Under Clinical Evaluation -- 15.3.2 Clinically Qualified Source Materials -- 15.4 Consensus Standards for Cell Banking -- 15.4.1 Ethics -- 15.4.2 Data Standardisation -- 15.5 Basic Scientific Developments Impacting on Quality Control and Safety -- 15.5.1 Genetic and Epigenetic Instability Affecting Lineage and Oncogenic Potential -- 15.6 Summary -- References -- Index.Tissue banksProcurement of organs, tissues, etcPreservation of organs, tissues, etcBancs de teixitsthubConservació de teixits (Biologia)thubConservació d'òrgansthubLlibres electrònicsthubTissue banks.Procurement of organs, tissues, etc.Preservation of organs, tissues, etc.Bancs de teixitsConservació de teixits (Biologia)Conservació d'òrgans362.1783Turner MarcZahra SharonGalea GeorgeMiAaPQMiAaPQMiAaPQBOOK9910488724503321Essentials of Tissue and Cells Banking2208911UNINA